Ai Feedback
Exact(4)
The major objective response rate was 47.7%95%5% confidence interval (CI), 33.8 62.1%).
A comparable response rate was observed for adenocarcinoma and squamous carcinoma patients as 8 of the 24 patients with adenocarcinoma had a major objective response (33.3%), while none of the 9 patients with squamous carcinoma had a major objective response.
Overall, 10 patients achieved a major objective response: one complete response (2.9%, 95% CI: 0 8.5%), and nine partial responses (26.5%, 95% CI: 11.7 41.2%).
A phase II study of the anti-EGFR inhibitor cetuximab monotherapy did not report any major objective response and the time to progression was only 6 months of recurrent or metastatic ACC (Locati et al, 2009b).
Similar(56)
Although a small fraction of NSCLC patients (∼10%) have major objective responses to EGFR-based therapy, the majority of NSCLC patients do not respond to EGFR-targeted therapies.
Major objective responses were observed in 24 patients (57%, 95% Confidence Interval (CI): 42 72%), including four complete responses (10%).
The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity.
No major objective responses were seen and the median survival time was only 39 weeks.
No major objective responses were observed and ten patients had stable disease.
Furthermore, 4 of 19 patients had major objective responses to subsequent anticancer therapies given immediately after epigenetic therapy.
Tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, block the aberrant activation of KIT, leading to major clinical benefits of objective response and durable disease control.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com